Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow
- PMID: 12042968
- DOI: 10.1007/s00330-001-1270-5
Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow
Abstract
The aim of this study was to differentiate normal, hypercellular, and neoplastic bone marrow based on its MR enhancement after intravenous administration of superparamagnetic iron oxides in patients with cancer of the hematopoietic system. Eighteen patients with cancer of the hematopoietic system underwent MRI of the spine before and after infusion of ferumoxides ( n=9) and ferumoxtran ( n=9) using T1- and T2-weighted turbo spin-echo (TSE) and short tau inversion recovery sequences (STIR). In all patients diffuse or multifocal bone marrow infiltration was suspected, based on iliac crest biopsy and imaging such as conventional radiographs, MRI, and positron emission tomography. In addition, all patients had a therapy-induced normocellular ( n=7) or hypercellular ( n=11) reconversion of the normal non-neoplastic bone marrow. The MRI data were analyzed by measuring pre- and post-contrast signal intensities (SI) of hematopoietic and neoplastic marrow and by calculating the enhancement as deltaSI(%) data and the tumor-to-bone-marrow contrast as contrast-to-noise ratios (CNR). Changes in bone marrow signal intensity after iron oxide administration were more pronounced on STIR images as compared with T1- and T2-weighted TSE images. The STIR images showed a strong signal decline of normal and hypercellular marrow 45-60 min after iron oxide infusion, but no or only a minor signal decline of neoplastic bone marrow lesions; thus, deltaSI% data were significantly higher in normal and hypercellular reconverted marrow compared with neoplastic bone marrow lesions ( p<0.05). Additionally, the contrast between focal or multifocal neoplastic bone marrow infiltration and normal bone marrow, quantified by CNR data, increased significantly on post-contrast STIR images compared with precontrast images ( p<0.05). Superparamagnetic iron oxides are taken up by normal and hypercellular reconverted bone marrow, but not by neoplastic bone marrow lesions, thereby providing significantly different enhancement patterns on T2-weighted MR images; thus, superparamagnetic iron oxides are useful to differentiate normal and neoplastic bone marrow and to increase the bone marrow-to-tumor contrast.
Similar articles
-
Ferumoxtran-10-enhanced MR imaging of the bone marrow before and after conditioning therapy in patients with non-Hodgkin lymphomas.Eur Radiol. 2006 Mar;16(3):598-607. doi: 10.1007/s00330-005-0045-9. Epub 2005 Nov 12. Eur Radiol. 2006. PMID: 16284770
-
Ultrasmall superparamagnetic iron-oxide-enhanced MR imaging of normal bone marrow in rodents: original research original research.Acad Radiol. 2005 Sep;12(9):1190-7. doi: 10.1016/j.acra.2005.05.014. Acad Radiol. 2005. PMID: 16099684
-
Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors.AJNR Am J Neuroradiol. 2002 Apr;23(4):510-9. AJNR Am J Neuroradiol. 2002. PMID: 11950637 Free PMC article.
-
Hepatic MRI with SPIO: detection and characterization of focal liver lesions.Eur Radiol. 1998;8(7):1198-204. doi: 10.1007/s003300050535. Eur Radiol. 1998. PMID: 9724439 Review.
-
The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10.Cancer Biomark. 2009;5(2):69-73. doi: 10.3233/CBM-2009-0579. Cancer Biomark. 2009. PMID: 19414923 Review.
Cited by
-
Speeding up PET/MR for cancer staging of children and young adults.Eur Radiol. 2016 Dec;26(12):4239-4248. doi: 10.1007/s00330-016-4332-4. Epub 2016 Apr 5. Eur Radiol. 2016. PMID: 27048532 Free PMC article.
-
MR imaging of therapy-induced changes of bone marrow.Eur Radiol. 2007 Mar;17(3):743-61. doi: 10.1007/s00330-006-0404-1. Epub 2006 Sep 21. Eur Radiol. 2007. PMID: 17021706 Free PMC article. Review.
-
The evolving role of MRI in oncohaematological disorders.Radiol Med. 2007 Aug;112(5):703-21. doi: 10.1007/s11547-007-0174-0. Epub 2007 Jul 24. Radiol Med. 2007. PMID: 17653627 Review. English, Italian.
-
Characterization of carotid artery plaques with USPIO-enhanced MRI: assessment of inflammation and vascularity as in vivo imaging biomarkers for plaque vulnerability.Int J Cardiovasc Imaging. 2011 Jul;27(6):901-12. doi: 10.1007/s10554-010-9736-7. Epub 2010 Oct 24. Int J Cardiovasc Imaging. 2011. PMID: 20972832
-
MRI and PET in monitoring response in lymphoma.Cancer Imaging. 2005 Nov 23;5 Spec No A(Spec No A):S106-12. doi: 10.1102/1470-7330.2005.0038. Cancer Imaging. 2005. PMID: 16361125 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical